Interplay Between Microglia and Alzheimer's Disease-Focus on the Most Relevant Risks: APOE Genotype, Sex and Age

Yanting Chen1, Tingting Hong1, Feng Chen1

  • 1Guangdong Key Laboratory of Age-Related Cardiac and Cerebral Diseases, Department of Neurology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.

Insights

Microglia, the brain's immune cells, play a critical role in Alzheimer's disease (AD) progression. Key risk factors like APOE genotype, sex, and aging interact with microglia, exacerbating neurodegeneration and offering potential therapeutic targets.

Area of Science:

  • Neuroscience and Immunology
  • Central Nervous System (CNS) Immune Cell Function
  • Neurodegenerative Disease Pathogenesis

Background:

  • Microglia are essential for CNS homeostasis, development, and repair.
  • Dysregulated microglial activation is implicated in neurodegenerative diseases, notably Alzheimer's disease (AD).
  • Classic AD pathologies, amyloid-beta (Aβ) and Tau, are associated with microglial activation, an early pathogenic event.

Purpose of the Study:

  • To review the role of microglia in AD progression.
  • To examine the interaction between microglia and major AD risk factors: apolipoprotein E (APOE) genotype, sex, and aging.
  • To explore potential therapeutic strategies targeting microglial dysfunction in AD.

Main Methods:

  • Literature review focusing on microglial function in AD.
  • Analysis of studies investigating the influence of APOE genotype, sex, and aging on microglial activity in AD models.
  • Synthesis of current understanding of microglial involvement in AD pathogenesis.

Main Results:

  • APOE genotype, particularly APOE4, influences microglial Aβ clearance and can exacerbate Tau pathology.
  • Female microglia, protective under normal conditions, may accelerate AD progression in the disease state.
  • Aging increases microglial sensitivity, potentially worsening microglial dysfunction and AD severity.

Conclusions:

  • APOE genotype, sex, and aging synergistically interact with microglia to increase AD risk and progression.
  • Microglial dysfunction is a central component in AD pathogenesis driven by these risk factors.
  • Microglial depletion and replacement represent a promising therapeutic avenue for AD treatment.